Channing Tatum & Jenna Dewan-Tatum Show Off Baby Bump at Oscars









02/24/2013 at 06:45 PM EST







Channing Tatum and Jenna Dewan-Tatum


Jason Merritt/Getty


Who is your bump wearing?

Parents-to-be Channing Tatum and Jenna Dewan-Tatum brought a very special guest to Sunday night's 85th Annual Academy Awards – wearing a black lace, backless dress, Dewan-Tatum, 32, showed off her new curves, while husband Tatum revealed where their baby will be born.

"I'm walking the carpet, trying to keep it together tonight but we're good!" a radiant Dewan-Tatum told Ryan Seacrest on the red carpet Sunday night.

When asked by Seacrest if the couple had any plans to slow down for some "family time," Tatum, 32, replied: "We're gonna actually have the baby in London while I'm shooting so there will be no downtime whatsoever after that."

Tatum – who was named PEOPLE's 2012 Sexiest Man Alive – recently told PEOPLE that he's doing his homework before the baby arrives.

"I have never changed a diaper before, so I may need some help learning," the actor said at the time. "I don't have friends who have kids, so it's going to be an interesting experience to learn how to change a diaper."

The couple's first child is due this summer.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Brown's school funding plan draws mixed reactions









In the Anaheim City School District, where most students are low-income and struggling to learn English, teachers need special training, extra tutoring time and lots of visual materials to help their pupils achieve at grade level.


In the well-heeled Palos Verdes Peninsula Unified School District, poverty and limited English are not widespread problems. But officials there say their student needs include more expensive Advanced Placement classes to challenge them with college-level material in high school.


Who should get more state educational dollars? Last week, school districts got their first glimpse of how that question would be answered under Gov. Jerry Brown's proposed new funding formula: Anaheim would receive an estimated $11,656 per student annually; Palos Verdes would get $8,429 by the time the plan is fully implemented in seven years.





And that disparity draws distinctly different reactions.


"It's great news," said Darren Dang, Anaheim's assistant superintendent of administrative services. "Given our demographics, we'll be getting much-needed resources for our students."


But Lydia Cano, Palos Verdes' deputy superintendent of business services, said she believed the new scheme would shortchange her students. Disadvantaged students already receive a bigger share of state and federal dollars, she said.


"It's not fair," she said. "It will make the divide even bigger."


In the most significant change in four decades in how school dollars would be distributed, Brown is proposing to give all districts a base grant, then add an extra 35% of that for each student who is low-income, struggling with English or in foster care. If such students make up more than 50% of a district's population, another 35% supplement would be given.


The formula is part of Brown's proposed budget, which requires the Legislature's approval.


Under the proposal, the state would do away with most so-called categorical funding — which was earmarked for such specific uses as textbooks, remediation and low-income student aid. Instead, the money would be given directly to districts with no strings attached, to promote Brown's goal of greater local control.


The plan is aimed at reforming what most educators agree is an inequitable, burdensome and overly complex funding system. It is grounded in a 2008 report coauthored by state Board of Education President Michael Kirst that compiled research showing that parental income and English language ability are two critical factors in academic achievement.


Kirst argued that it was more important to help needy students gain grade-level skills than it is to provide college-level work for top-achieving high schoolers. "These are judgments about political priorities," he said.


About 20 states currently distribute extra dollars to needier students, including Rhode Island and New York, according to Margaret Weston of the Public Policy Institute of California. Poor districts in California already receive about 20% more in state and federal dollars than do affluent ones, but Brown's formula would increase that share, she said.


After four years of crippling budget cuts, the Los Angeles Unified School District is expected to receive an estimated boost of $820 more per student over the next two years under Brown's proposal. By 2020, funding is expected to grow to $11,993 per student from $7,509 last year.


L.A. Supt. John Deasy hailed the governor's proposal. "It's morally the right thing to do and educationally the sound thing to do," he said.


Like many administrators, however, Deasy cautioned that it would take a few years of increases to make up for the state's devastating reductions since 2007. New spending could possibly begin in 2015, he said, adding that he would recommend restorations in summer school, counselors, arts and support staff, among other things.


He also said he would make it the district's "policy and practice" to send the state dollars for disadvantaged students directly to their schools to help them. Some officials, such as Dang in Anaheim, have expressed concerns about possible pressure to use the money for salary hikes.


Over the next five years, per-student funding is expected to grow by about $2,700, the state estimates showed. All school districts and charter schools would receive at least as much money this year as last.


In Los Angeles County, funding estimates range from a low of $7,863 per student in the Hermosa Beach City School District to $13,569 for Animo Leadership High, an independent charter school in Inglewood.


Long Beach, San Bernardino City and Santa Ana unified all are estimated to receive funding boosts of $800 to $1,000 per student over the next two years. But the state projects an increase of less than half that for more affluent districts, such as San Marino, Palos Verdes Peninsula and Manhattan Beach unified.


Julie Boucher, San Marino's assistant superintendent of business services, said she was dismayed that Brown was not proposing to first restore general funding that the state has cut since 2007 before allocating additional dollars to specific students.


San Marino's state funding has been slashed by $17 million since 2008 — a total equivalent to 60% of its annual budget. The district has received $3.1 million annually from its nonprofit fundraising foundation and $5.1 million from a parcel tax but still has worked with its employee unions to freeze salaries, require larger contributions for healthcare, cut 26 teaching positions and shorten the school calendar with unpaid furlough days, she said.


"It does not seem equitable given the fact that we're all down," she said of Brown's proposal. "First we need to be made whole. Don't rob Peter to pay Paul."


During a recent visit to Ponderosa Elementary School in Anaheim, however, educators demonstrated how teaching lower-income English learners is more costly and time-consuming.


In Bernadette Grzechowiak's fifth-grade classroom, for instance, students were learning how to find main ideas in a passage about Native Americans. But unlike fluent English speakers, she said, those with limited language skills need far more visual aids — presented every 60 to 90 seconds, according to research. Her room is filled with graphics about colonial America and sentence frames to teach them academic language, such as "One detail that supports the main idea is…"


Grzechowiak said she learned those and other techniques from a district-paid teaching coach.


Ponderosa has also spent $10,000 on a science book series heavy on photos and graphics to help students learning English. And the school has two full-time teachers to provide extra support for struggling students and a bilingual community liaison to help educate the school's largely immigrant parents about their children's academic needs.


"Kids are so hungry and ready to learn," said Maria Villegas, the principal. "It just takes time, opportunity and having a great staff."


teresa.watanabe@latimes.com





Read More..

Syrian Flood Into Lebanon Stirs Fear of Looming Disaster





QAA, Lebanon — Quietly but inexorably, a human tide has crept into Lebanon, Syria’s smallest and most vulnerable neighbor.




As Syrians fleeing civil war pour over the border, the village priest here, Elian Nasrallah, trudges through muddy fields to deliver blankets. His family runs a medical clinic for refugees. When Christian villagers fret about the flood of Sunni Muslims, he replies that welcoming them is “the real Christianity.”


But the priest and his parishioners cannot keep up. The United Nations counts more than 305,000 Syrian refugees in Lebanon, but local officials and aid workers say the actual number is about 400,000, saturating this country of four million.


The Lebanese government — by design — has largely left them to fend for themselves. Deeply divided over Syria, haunted by memories of an explosive refugee crisis a generation ago, it has mostly ignored the problem, dumping it on overwhelmed communities like Qaa.


So far, Lebanon’s delicate balance has persevered, but there is a growing sense of emergency.


Sectarian tensions are rising. Fugitive Syrian rebels in border villages have clashed with Lebanese soldiers. The government’s anemic response has delayed international aid. Local volunteers are running out of cash and patience.


And the battle for Damascus, Syria’s capital, has barely begun. Should fighting overwhelm that religiously and politically mixed city of 2.5 million a half-hour drive from Lebanon, the Lebanese fear a cataclysm that could sweep away their tenuous calm.


“There is a limit to what the country can handle,” said Nadim Shubassi, mayor of Saidnayel, a Sunni town now packed with Syrians. “Maybe we have reached this limit now.”


Lebanon’s refugee crisis does not match the familiar image of vast, centralized tent camps and armies of foreign aid organizations. It is nowhere, and everywhere. Displaced Syrians seem to fill every nook and cranny: half-finished cinder block houses, stables, crowded apartments.


It is easy to miss them, until a second glance. Drying laundry peeks from construction sites. Bedsheets hang in shop windows, concealing stark living spaces. Daffodil sellers, shoeshine men, women and children begging in Beirut — all incant, “Min Suria.” From Syria.


At first, most refugees — mainly Sunnis, like most of the rebels fighting Syria’s government — headed for friendly Sunni areas. Now, those communities are swamped and resentful, and Syrians are spreading to places where they fit less comfortably, from Christian mountain villages to the Mediterranean city of Tyre in the southern Shiite Muslim heartland.


They are moving, with some trepidation, into Qaa, in the northern Bekaa Valley, the territory of the powerful Shiite militia Hezbollah, which is allied with Syria’s government and, to many refugees, just as fearsome.


As they flee increasingly sectarian killing, Syrians layer their fears onto those of a country deeply scarred by its own generation-long sectarian civil war. They are testing, yet also relying on, the fragile yet flexible balance that has endured here, punctured by occasional fighting, since Lebanon’s war ended 22 years ago.


In Baalbek, a Hezbollah stronghold where a poster of the Syrian president, Bashar al-Assad, grins down on a busy street, refugees turn to Sawa, a community group that views helping them as embodying its nonsectarian mission. Still, they rattle Abbas Othman, a Sawa member.


“We are worried they will bring their civil war here,” he said.


One recent evening in Qaa, Mr. Nasrallah, the priest, stood outside a burlap shack that sheltering a Syrian family of 12. They clamored around him; they had eaten only potatoes that day. Cold crept in as a blue dusk fell. One man implored, “You are responsible for us!”


The priest threw up his hands.


“It’s wartime,” he said. “Is the government doing its job or not?”


Lebanese decision-makers wanted it this way, at first. A year ago, just 5,000 Syrians had fled here, and Hezbollah, Lebanon’s most powerful political party, denied any sense of crisis.


Reporting was contributed by Hwaida Saad, Hania Mourtada, Ben Solomon and Lynsey Addario.



Read More..

Predict the Oscar Winners!






  • Facebook

  • Tweet








  • Facebook

  • Tweet






Cast your vote for who will be the night's big winners Click here to download a printable ballot.






Click here to download a printable ballot.


Polls
completed:




Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

L.A.'s next mayor will face stark budget problems









Brad Smith used to consider himself a Los Angeles booster. But lately, the 48-year-old grows melancholy when he drives around the San Fernando Valley where he grew up.


The parks look worn-out. The sidewalks are broken. Street trees go untended. And don't even get him started on the sorry state of the Granada Hills pool.


"Every place I used to go as a kid, it's tired, it's old, it's beaten up," said Smith, a project manager at an engineering firm who made a losing run for City Council two years ago out of frustration. "Other cities manage to maintain older facilities. I'm not really certain why Los Angeles can't do a better job."





As Los Angeles voters head to the polls to pick a successor to Mayor Antonio Villaraigosa, Smith's question, or some version of it, is being asked over and over again in neighborhoods across the city.


Here's the short answer: To stay afloat financially, the city cut hundreds of millions of dollars out of everyday services and ongoing maintenance.


But the deeper causes are more complex, and include costly, ill-timed spending commitments at City Hall and a failure to adjust to the region's weakening economic foundation.


A Times review of the city's finances found:


• Just before the recession hit, city leaders agreed to add hundreds of police officers to the payroll and give much of the city's civilian workforce 25% raises over five years. The twin decisions — supported by mayoral candidates Eric Garcetti, Jan Perry and Wendy Greuel — added major stress to the budget as the downturn began.


• Over the next five years, officials slashed 5,300 positions, or nearly 15% of the city workforce, and scaled back services ranging from sidewalk repairs to 911 rescue units. Despite the cuts and additional concessions by employee unions, the city's salary costs remain the same as when the economic crisis began: $2.7 billion a year.


• The city faces even more service cuts if it fails to achieve what critics say are optimistic predictions of pension investment returns in coming years.


The next mayor will have to confront how and whether to restore services and keep police staffing at a historic high. Paying for it all will require either new revenues, or new concessions from city employees, or new approaches to running vital city programs.


The top mayoral candidates tend to sidestep specifics on these questions, describing "growing the economy" as their primary solution. Other city leaders are hoping for passage a half-cent sales tax increase. That tax is warranted after so many tough decisions, said Miguel Santana, the top budget official at City Hall.


"We can see the light at the end of the tunnel," he said.


Community activists say the next mayor needs to break the cycle of decreasing services and raising fees, fines and taxes to offset rising personnel costs. "What the city has done for the last five years is ... tread water," said San Pedro resident Doug Epperhart, a city commissioner overseeing Los Angeles' network of neighborhood councils.


::


Underlying Los Angeles' current troubles, according to many economists, are well-documented, long-term shifts in the region's economy.


After half a century as one of the nation's wealthiest and most technologically important cities, the Los Angeles area began to falter after the end of the Cold War. Since 1990, the nation's total employment has grown 23%, while the number of local jobs has shrunk 7%, according to the UCLA Anderson Forecast, which tracks economic trends.


The situation appears to have worsened recently, UCLA economist William Yu said. The great recession hit Los Angeles especially hard and since then, its recovery has been weaker. "The economy is not healthy at all," Yu added.


Over the past two decades, Los Angeles lost almost every sector that mattered to the middle class: automobiles, steel, shipbuilding and, of course, aerospace. In all, 56% of manufacturing jobs, or nearly half a million positions, have disappeared.


The change is reflected in income statistics for that period. Nationally, personal income has increased by 2.4% per year, adjusted for inflation. Locally, it grew at half that rate.





Read More..

The Saturday Profile: Pavel Astakhov: The Man Behind U.S. Adoption Ban


Mikhail Metzel/Associated Press


Pavel A. Astakhov at a news conference in Moscow last month.







MOSCOW — Long before joining the federal government as Russia’s child rights commissioner and, more recently, becoming the leading force behind a ban on the adoption of Russian children by Americans, Pavel A. Astakhov transformed himself into a celebrity lawyer with mass market appeal — no small trick in a country where encounters with the legal system are as desirable as a tooth extraction.




There was “The Hour of Trial with Pavel Astakhov,” a courtroom reality television show casting him as Russia’s Judge Judy along with a radio program of the same name. There was a second radio program called “Advocacy Defense Techniques of Pavel Astakhov”; a series of books titled “Your Attorney: Pavel Astakhov,” with installments on housing, property rights, inheritance, pensions and family law; several legal-thriller novels fashioned in the tradition of John Grisham; a seminar series called “Pavel Astakhov’s School of Advocacy Skills”; and a law firm named the Pavel Astakhov Moscow City Law Bar.


The law banning adoptions by Americans was not named after him, but it might as well have been.


In the weeks before and after the law was approved by Parliament and signed by President Vladimir V. Putin, Mr. Astakhov was its loudest and most visible champion, insisting that Russia take care of its own orphans and not sell them to foreigners.


And it was Mr. Astakhov who this week stoked a furor over the latest death of an adopted Russian child in the United States, Max Shatto, with a post on Twitter that said: “Urgent! In the state of Texas, an adoptive mother killed a 3-year-old Russian child.”


Investigators say the circumstances of that death remain murky, and Mr. Astakhov has backed away from the murder accusation — but only slightly. At a news conference, he equated the boy’s mother, Laura Shatto, with two adoptive fathers, Miles Harrison of Virginia and Brian Dykstra of Iowa, who were acquitted of killing their toddler sons.


“Well, the presumption of innocence, you know how it is — sometimes it becomes so rigid,” Mr. Astakhov said.


Referring to the acquittals of Mr. Harrison and Mr. Dykstra, he declared, “For everyone it was completely clear that in one way or another they were guilty for the deaths of their children.”


In frequent television appearances, Mr. Astakhov denounces international adoptions in general as a sinister, profit-driven business, and he is pushing to extend the ban to all countries. He has been advocating that since 2010 after a woman in Tennessee put her 7-year-old adopted son on a flight back to Russia alone, with a note saying, “I no longer wish to parent this child.”


THIN, impeccably dressed and telegenically handsome with perfectly coifed hair that occasionally glints with an unnatural shade of bronze, Mr. Astakhov delivers nearly every statement that he makes with the silver-tongued flair of a courtroom closing argument.


“Don’t present me as an America-hater,” Mr. Astakhov, who holds a Master of Laws degree from the University of Pittsburgh, said after a recent news conference. “I am a fighter for the rights of Russian children. I am fighting with those who violate children’s rights.”


He added: “I am only saying that it’s a shame that Russia is giving away its children. America does not give away its children, does it?”


But he also often peppers his remarks with references to abusive American parents who he says have mostly escaped proper punishment, calling them “bastards” and “pedophiles.”


In response to his aggressive promotion of the ban, critics have denigrated his nationalist statements as hypocrisy, noting that the eldest of Mr. Astakhov’s three biological children attended private schools in England and the United States, while the youngest was born in 2009 in the same private hospital in Nice, France, where Angelina Jolie gave birth to twins.


A magazine spread showed Mr. Astakhov; his wife, Svetlana; and their children posing in luxurious surroundings in France where they spend the summers, and in an accompanying article he marveled at the prenatal care that his wife received, saying that while pricey it was still cheaper than elite maternity hospitals in Russia.


Read More..

Danica Patrick Opens Up About Dating Competitor Ricky Stenhouse, Jr.















02/22/2013 at 07:25 PM EST







Danica Patrick and Ricky Stenhouse Jr.


Tom Pennington/NASCAR/Getty


Danica Patrick knows mixing business with pleasure isn't wise, but it's not stopping her.

"I don't think it was a good idea. [But] there was nothing I could do about it," she tells menshealth.com of getting into a relationship with fellow NASCAR racer, Ricky Stenhouse, Jr., 25. "You can't tell your heart who to like and not like. It just happened."

Patrick, 30, isn't worried about running into a future ex-boyfriend on the racetrack.

"I know I'm setting myself up for that," she says with a laugh. "But I choose not think about that possibility right now. I'm going to be positive."

For now, the competition is friendly between the history-making superstar – who announced her split from husband Paul Hospenthal in November – and her new beau.

"Ricky and I have always had that situation where we give each other room [on the track]," Patrick says. "We respect each other on the track. I don't see any reason for that to change."

But despite the relationship, business is still business, and if something happened to her man mid-competition, she'd leave his care to handlers and continue on with the race.

"We both understand that this is a dangerous sport," she says. "We know that things will happen, and we have faith in the safety of the cars and the tracks and the medical staff. If something did happen to him, there's nothing I could do to help. I'd just have to remember that everything that needed to be done to make him safe was being done."

Patrick, meanwhile, is set for the coveted pole position for her second turn in the Daytona 500 Sunday.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..